物理治疗因子在银屑病甲营养不良治疗中的应用

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

背景。银屑病甲营养不良(Psoriatic Onychodystrophy, POD,银屑病甲损害)是银屑病的常见临床表现之一。通常伴随明显疼痛,影响患者穿鞋,穿袜及日常活动,显著降低生活质量,并可能诱发焦虑和抑郁。研究表明,非药物治疗方法,特别是 脉冲染料激光(Pulsed Dye Laser, PDL)和 中频脉冲电流疗法(达森瓦尔疗法,Darsonval Therapy),可有效改善银屑病甲损害的临床症状。

研究目的。 评估脉冲染料激光和达森瓦尔疗法联合应用在银屑病甲营养不良综合治疗中的临床疗效。

材料与方法。本研究为 前瞻性,对照,随机研究,共纳入 110 例银屑病甲营养不良患者,采用 简单固定随机化 方法分为四组。第 1 组(对照组,n=27):仅接受基础治疗(Basic Therapy, BT),即局部涂抹卡泊三醇软膏。第 2 组(比较组 1,n=28):在BT 基础上增加3个疗程的达森瓦尔疗法。第 3 组(比较组 2,n=28):在 BT 基础上 增加 5-6次脉冲染料激光治疗(每月 1 次)。第 4 组(主要研究组,n=27):在 BT 基础上 联合应用达森瓦尔疗法和脉冲染料激光治疗。临床评估指标包括甲基质和甲床病变的发生率,以及银屑病甲严重指数(Nail Psoriasis Severity Index, NAPSI)和皮肤病生活质量指数(Dermatology Life Quality Index, DLQI)评分。

结果。基线 NAPSI 评分显示,患者 甲床和甲基质 均有广泛受累。初始 DLQI 评分为 23.6 分,表明 指甲病变对患者生活质量产生显著负面影响。所有治疗组均显示 临床改善,但改善程度与治疗方案相关。物理治疗因子的联合应用进一步提高了疗效,其中达森瓦尔疗法和脉冲染料激光的联合治疗取得了最佳临床效果。

结论。在 标准治疗方案 的基础上 增加物理治疗手段 可 显著提高银屑病甲损害的治疗效果。联合应用 脉冲染料激光 和 达森瓦尔疗法 能 最大程度缓解临床症状,并显著提高患者的生活质量。

全文:

受限制的访问

作者简介

Alesya Yu. Blokina-Mechtalina

Mechtalina Clinic

编辑信件的主要联系方式.
Email: alesya_mechtalina@mail.ru
ORCID iD: 0009-0002-3223-8622
俄罗斯联邦, Zhukovsky

Natalia B. Korchazhkina

Central State Medical Academy

Email: n9857678103@gmail.com
ORCID iD: 0000-0001-6913-8778
SPIN 代码: 9733-7646

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Sergey N. Nagornev

Central State Medical Academy

Email: drnag@mail.ru
ORCID iD: 0000-0002-1190-1440
SPIN 代码: 2099-3854

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

参考

  1. All-Russian public organization “Russian society of dermatovenerologists and cosmetologists”. Clinical guidelines. Psoriasis. M., 2023. 78 p. (In Russ.)
  2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6
  3. Canal-García E, Bosch-Amate X, Belinchón I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliográficas. 2022;113(5):481-490. English, Spanish. doi: 10.1016/j.ad.2022.01.006
  4. Kaeley GS, Eder L, Aydin SZ, et al. Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs. Journal of Rheumatology. 2021;48(8):1208-1220. doi: 10.3899/jrheum.201471
  5. Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131-135. doi: 10.5114/reum.2017.68912
  6. Reich K. Approach to managing patients with nail psoriasis. Journal of the European Academy of Dermatology and Venereology. 2009;23 Suppl 1:15-21. doi: 10.1111/j.1468-3083.2009.03364.x
  7. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail Psoriasis, the unknown burden of disease. Journal of the European Academy of Dermatology and Venereology. 2014;28(12):1690-5. doi: 10.1111/jdv.12368
  8. Alavi MAM. Psoriatic onychodystrophy. Bulletin of Postgraduate Medical Education. 2022;1:38–50.
  9. Gisondi P, Gracia-Cazaña T, Kurzen H, Galván J. Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids. Journal of Clinical Medicine. 2024;13(15):4484. doi: 10.3390/jcm13154484
  10. Fineshina YeI. PUVA-vanny v vosstanovitel’nom lechenii psoriaticheskoy onikhodistrofii [dissertation]. Moscow; 2010. Available from: https://www.dissercat.com/content/puva-vanny-v-vosstanovitelnom-lechenii-psoriaticheskoi-onikhodistrofii?ysclid=m4mm4q3ilz 411068300.
  11. Peruzzo J, Garbin GC, Maldonado G, Cestari TF. Nail psoriasis treated with pulsed dye laser. Anais Brasileiros de Dermatologia. 2017;92(6):885-887. doi: 10.1590/abd1806-4841.20175918
  12. Al-Mutairi N, Noor T, Al-Haddad A. Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis. Dermatology and Therapy. 2014;4(2):197-205. doi: 10.1007/s13555-014-0057-y
  13. Bovenschen HJ, Erceg A, Van Vlijmen-Willems I, et al. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization. Journal of Dermatological Treatment. 2007;18(1):32-9. doi: 10.1080/09546630601028760
  14. Liu A, Moy RL, Ross EV, et al. Pulsed dye laser and pulsed dye laser-mediated photodynamic therapy in the treatment of dermatologic disorders. Dermatologic Surgery. 2012;38(3):351-66. doi: 10.1111/j.1524-4725.2011.02293.x
  15. Alavi MAM, Monaenkova MK, Molochkov AV, et al. Use of PUVA therapy in combination with darsonvalization in the treatment of psoriatic onychodystrophy. Biomedical Photonics. 2023;12(S4):49–50.
  16. Kulikova NG, Alavi MAM. Darsonvalization method in combination with PUVA therapy in the treatment of patients with psoriatic onychodystrophy. Resort Medicine. 2023;1:69–73. doi: 10.51871/2304-0343_2023_1_69
  17. Zou Q, Luo Y, Hao D, et al. Validation and application of the Dermatology Life Quality Index score, a modification of the DLQI score, in psoriasis patients. Journal of Health, Population and Nutrition. 2024;43(1):92. doi: 10.1186/s41043-024-00587-3
  18. Kusuba N, Kitoh A, Dainichi T, et al. Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue. Journal of Allergy and Clinical Immunology. 2018;141(3):972–981.e10. doi: 10.1016/j.jaci.2017.07.033
  19. Segaert S, Ropke M. The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis. Journal of Drugs in Dermatology. 2013;12(8):e129–37.
  20. Mori H, Arita K, Yamaguchi T, et al. Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice. Kobe Journal of Medical Sciences. 2016;62(4):E79–E88
  21. Germán B, Wei R, Hener P, et al. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight. 2019;4(2):e123390. doi: 10.1172/jci.insight.123390
  22. Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(15):3387. doi: 10.3390/nu15153387
  23. Karakawa M, Kishimoto M, Ohtsuki M, Komine M. Calcipotriol induces the production of CTACK/CCL27, one of the potential suppressive factors in psoriasis inflammation. Journal of Dermatology. 2021;48(12):1949-1950. doi: 10.1111/1346-8138.16152
  24. Zhang J, Fang H, Wang R, et al. Effect of Calcipotriol on IFN-γ-Induced Keratin 17 Expression in Immortalized Human Epidermal Keratinocyte Cells. Medical Science Monitor. 2017;23:6049–6056. doi: 10.12659/msm.904850
  25. Körver JE, Vissers WH, van Rens DW, et al. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. British Journal of Dermatology. 2007;156(1):130–7. doi: 10.1111/j.1365-2133.2006.07561.x
  26. Tiberio R, Bozzo C, Pertusi G, et al. Calcipotriol induces apoptosis in psoriatic keratinocytes. Clinical and Experimental Dermatology. 2009;34(8):e972-4. doi: 10.1111/j.1365-2230.2009.03518.x
  27. Franssen ME, de Jongh GJ, van Erp PE, van de Kerkhof PC. A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations. Acta Dermato-Venereologica. 2004;84(3):195-200. doi: 10.1080/00015550410025930
  28. Thatai P, Khan AB. Management of nail psoriasis by topical drug delivery: a pharmaceutical perspective. International Journal of Dermatology. 2020;59(8):915–925. doi: 10.1111/ijd.14840
  29. Saner MV, Kulkarni AD, Pardeshi CV. Insights into drug delivery across the nail plate barrier. Journal of Drug Targeting. 2014;22(9):769–89. doi: 10.3109/1061186X.2014.929138
  30. Haghsay Khashechi E, Afaghmehr A, Heydari N, et al. Laser-mediated Solutions: Breaking Barriers in Transdermal Drug Delivery. AAPS PharmSciTech. 2024;25(6):142. doi: 10.1208/s12249-024-02849-z
  31. Wenande E, Anderson RR, Haedersdal M. Fundamentals of fractional laser-assisted drug delivery: An in-depth guide to experimental methodology and data interpretation. Advanced Drug Delivery Reviews. 2020;153:169–184. doi: 10.1016/j.addr.2019.10.003
  32. Rácz E, de Leeuw J, Baerveldt EM, et al. Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. Lasers in Surgery and Medicine. 2010;42(3):201–10. doi: 10.1002/lsm.20898
  33. Kuo YR, Wu WS, Jeng SF, et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers in Surgery and Medicine. 2005;36(1):38–42. doi: 10.1002/lsm.20104
  34. Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. Journal of the European Academy of Dermatology and Venereology. 2009;23(8):891–5. doi: 10.1111/j.1468-3083.2009.03196.x
  35. Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers in Medical Science. 2018;33(1):173–180. doi: 10.1007/s10103-017-2360-1
  36. Battista T, Scalvenzi M, Martora F, et al. Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clinical, Cosmetic and Investigational Dermatology. 2023;16:1899–1932. doi: 10.2147/CCID.S417679
  37. Taganov AV, Molochkov AV, Kulikova NG, et al. Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects. Russian Journal of Skin and Venereal Diseases. 2023;26(6):575–596. (In Russ). doi: 10.17816/dv570289
  38. Alavi MAM, Monaenkova MK, Molochkov AV, et al. PUVA therapy and high-frequency pulsed sinusoidal current of high voltage and low power in the treatment of patients with psoriatic onychodystrophy. Biomedical Photonics. 2023;12(S4):12–13.
  39. Nemchaninova OB, Lykova SG, Pozdnyakova ON, et al. The clinical effectiveness of the application of interferential currents for the combined treatment of onychopathies associated with psoriasis and eczema. Problems of Balneology, Physiotherapy and Exercise Therapy. 2016;93(3):4245. (In Russ.). doi: 10.17116/kurort2016342-45
  40. Starodubtseva NL. Izucheniye roli IL-17 v patogeneze psoriaticheskogo protsessa [dissertation]. Moscow; 2011. Available from: https://www.dissercat.com/content/izuchenie-roli-il-17-v-patogeneze-psoriaticheskogo-protsessa?ysclid=m4modnt0vc925434122.
  41. Benkov AA, Nagornev SN, Frolkov VK, Puzyreva GA. Efficiency of combined use of physiotherapeutic factors on the model of microcirculatory-tissue systems. Systems analysis and control in biomedical systems. 2021;2:8–17. doi: 10.36622/VSTU.2021.20.2.001
  42. Ulashchik VS. Combined physical therapy: general information, interaction between physical factors. Problems of Balneology, Physiotherapy and Exercise Therapy. 2016;93(6):411. doi: 10.17116/kurort201664-11
  43. Benkov AA, Nagornev SN, Frolkov VK, et al. Analysis of the mechanisms of synergistic effects in the combined use of physiotherapeutic factors. Physiotherapist. 2021;6:77–87. doi: 10.33920/med-14-2112-08

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2024



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86508 от 11.12.2023
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021
г.